AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8153291
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (AmBisome) 3 mg/kg/day for 10 days
Trial: 8153291
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (AmBisome) 100 mg (1.38-1.85 mg/kg) daily for 21 days
Trial: 12639652
Drug: Periprostatic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic injection of 10 mL of 2% lidocaine solution without epinephrine
Trial: 12639652
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL of 0.9% NaCl)
Trial: 11189013
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin for up to 4 weeks
Trial: 11189013
Drug: Metoprolol (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (intravenous then oral) for up to 4 weeks
Trial: 9202354
Drug: Right ventricle
RxNorm normalized name: Sus scrofa ventricle preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right ventricle to axillary patch configuration (12.7 +/- 5.9 J)
Trial: 9202354
Drug: Right ventricle
RxNorm normalized name: Sus scrofa ventricle preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right ventricle to superior vena cava plus axillary patch configuration (9.8 +/- 5.2 J)
Trial: 3963028
Drug: Flurbiprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (200 mg per day)
Trial: 3963028
Drug: Aspirin (4,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (4,000 mg per day)
Trial: 30917364
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy with intensive SBP goal < 120 mm Hg
Trial: 30917364
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy with standard SBP goal < 140 mm Hg
Trial: 30917364
Drug: Non-statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-statin therapy with intensive SBP goal < 120 mm Hg
Trial: 30917364
Drug: Non-statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-statin therapy with standard SBP goal < 140 mm Hg
Trial: 24433061
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg/day) for 12 weeks
Trial: 24433061
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor antagonists (ARBs)
Trial: 10468987
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy (0.036 U/kg/d)
Trial: 7595856
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy at the anaerobic threshold (AT) level continued after discharge (group T)
Trial: 7595856
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group C) with exercise therapy discontinued after discharge
Trial: 2112480
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g glucose and 120 g milk fat with 10 microCi U‐14C oleic acid given in the overnight fasting state
Trial: 2112480
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g glucose and 120 g milk fat with 10 microCi U‐14C oleic acid given 2 h after a carbohydrate-rich meal
Trial: 23026438
Drug: Umeclidinium 125
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium 125 μg
Trial: 25565796
Drug: Umeclidinium/vilanterol 125/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium/vilanterol 125/25 μg
Trial: 15848529
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of MMF or AZA to 75% and then to 50% of the original dose at 4 months and 8 months after inclusion.
Trial: 9024731
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) with nitroglycerin (NTG) infusion
Trial: 9024731
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) infusion alone
Trial: 2471718
Drug: SCH 434
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 434 (5 mg loratadine and 120 mg pseudoephedrine, administered twice daily)
Trial: 26995988
Drug: Early chemoradiotherapy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early chemoradiotherapy (CRT) without induction chemotherapy (IC) by capecitabine
Trial: 26995988
Drug: Whole brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole brain radiation therapy (historical control)
Trial: 24132975
Drug: Methyl-d9-choline (22%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl-d9-choline (22% of total choline intake, 480 or 930 mg/d)
Trial: 19745163
Drug: Inhibitor or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor or siRNA for endothelial NO synthase
Trial: 16283367
Drug: HRT- (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT- (no hormone replacement therapy)
Trial: 9077616
Drug: Chlorhexidine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.2% solution
Trial: 3711377
Drug: Tar oil
RxNorm normalized name: Tar oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tar oil applied twice daily with ultraviolet B phototherapy
Trial: 3711377
Drug: Oil vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil vehicle (an emollient) applied twice daily with ultraviolet B phototherapy
Trial: 30572580
Drug: D-allulose at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-allulose at doses of 0.1 g/kg·BW to 1.0 g/kg·BW
Trial: 30572580
Drug: D-allulose at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-allulose at 1.0 g/kg·BW
Trial: 10399047
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy according to Beck
Trial: 7554761
Drug: 99mTc‐DTPA (intra-arterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐DTPA (intra-arterial injection)
Trial: 7554761
Drug: 99mTc‐DTPA (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐DTPA (intravenous injection)
Trial: 7554761
Drug: 99mTc‐HSA (intra-arterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐HSA (intra-arterial injection)
Trial: 10216323
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of intravenous methylprednisolone
Trial: 31743812
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) lipid emulsion, reduced to 0.4 g/kg daily
Trial: 31743812
Drug: Olive/soybean (O/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive/soybean (O/S) lipid emulsion, reduced to 0.4 g/kg daily
Trial: 24886392
Drug: Intervention includes
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention includes provision of kits with necessary medicines and laboratory supplies for ANC, a storage system, a tracking system, and training sessions for health care providers.
Trial: 23206490
Drug: Intra-operative intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative intra-articular injection of magnesium sulphate and ropivacaine
Trial: 8135721
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy alone
Trial: 8135721
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy combined with desipramine
Trial: 2674084
Drug: Intravenous polyclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous polyclonal 90‐Yttrium (90Y) labeled antiferritin, 10 mCi (1 patient), 20 mCi (4 patients), or 30 mCi (2 patients)
Trial: 2674084
Drug: Intravenous polyclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous polyclonal 90‐Yttrium (90Y) labeled antiferritin
Trial: 46959
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of yttrium-90 (irradiation)
Trial: 30717707
Drug: Capecitabine with
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine with high-dose radiotherapy (arms C + D)
Trial: 30717707
Drug: Capecitabine with
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine with standard-dose radiotherapy (arms A + B)
Trial: 30717707
Drug: Capecitabine with
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine with high-dose radiotherapy and nelfinavir (arms A + C)
Trial: 30717707
Drug: Capecitabine with
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine with standard-dose radiotherapy and nelfinavir (arms B + D)
Trial: 25710876
Drug: Terbutaline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.5 mg) administered by inhalation 15 min before EVH
Trial: 25710876
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by inhalation 15 min before EVH
Trial: 19370171
Drug: Plitidepsin 7mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 7mg/m2 with L-carnitine (Arm B)
Trial: 19370171
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of L-carnitine
Trial: 11737438
Drug: 3% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% diclofenac gel in 2.5% hyaluronan gel
Trial: 11737438
Drug: Inactive gel
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive gel vehicle (placebo)
Trial: 9395759
Drug: Intravenous cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclosporine
Trial: 9067953
Drug: Cyclosporine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (high doses)
Trial: 9067953
Drug: Cyclosporine in
RxNorm normalized name: cyclosporine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine in combination with corticosteroids
Trial: 342619
Drug: Influenza virus
RxNorm normalized name: Influenza virus Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza virus vaccine (A/New Jersey/76 [Hsw1N1]) from four different manufacturers
Trial: 342619
Drug: Split‐product vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split‐product vaccine
Trial: 342619
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four vaccines
Trial: 342619
Drug: Split‐virus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split‐virus vaccine
Trial: 30880442
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing a mixture of carotenoids, vitamins and omega-3 fatty acids (1 tablet/day)
Trial: 29262509
Drug: Weitan Waifu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weitan Waifu patch
Trial: 25143719
Drug: Testosterone-enanthate (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone-enanthate (125 mg/week)
Trial: 22421906
Drug: 280 mg
RxNorm normalized name: levodopa 280 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 mg red wine polyphenols
Trial: 22421906
Drug: 560 mg
RxNorm normalized name: spinosad 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 mg red wine polyphenols
Trial: 22421906
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of polyphenol treatment
Trial: 2121359
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg, once daily)
Trial: 2121359
Drug: L-acetylcarnitine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetylcarnitine (500 mg, twice daily)
Trial: 219491
Drug: beta-blocker
RxNorm normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker
Trial: 219491
Drug: diuretic
RxNorm normalized name: Diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diuretic
Trial: 219491
Drug: central antihypertensive
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: central antihypertensive agent
Trial: 30981150
Drug: Experimental pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental pain induced by ultrasound‐guided injection of 1 mL hypertonic saline into the upper part of the right tibialis posterior muscle
Trial: 23569144
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg GTW daily, orally for 52 weeks
Trial: 23569144
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g 5-ASA daily, orally for 52 weeks
Trial: 21332551
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (500 mg every 12 h)
Trial: 21332551
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone (2.0 g per day for 7 days)
Trial: 19857627
Drug: Low-energy-density yogurt
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy-density yogurt with inulin (6 g)
Trial: 19857627
Drug: High-energy-density yogurt
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy-density yogurt (440 kcal; 0.9 kcal/g)
Trial: 19857627
Drug: Low-energy-density yogurt
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy-density yogurt (180 kcal; 0.4 kcal/g)
Trial: 16707864
Drug: 1% chloramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chloramine solution
Trial: 16707864
Drug: 10% formalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% formalin solution
Trial: 16707864
Drug: 0.02% thymol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% thymol solution
Trial: 16707864
Drug: ‐20 degrees
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ‐20 degrees C (no storage solution)
Trial: 15001599
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg daily)
Trial: 9232133
Drug: Remifentanil, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil, 1 microgram/kg, given over 30 s followed by a continuous infusion of 0.1 microgram.kg‐1.min‐1
Trial: 9232133
Drug: Remifentanil+midazolam, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil+midazolam, 0.5 microgram/kg, given over 30 s followed by a continuous infusion of 0.05 microgram.kg‐1.min‐1
Trial: 16154442
Drug: 24-hour continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour continuous intralipid infusion (20%, 0.4 mg mL(‐1) h(‐1))
Trial: 10895854
Drug: Pinitol 20
RxNorm normalized name: FOMITOPSIS PINICOLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinitol 20 mg x kg(‐1) x day(‐1) (n = 12)
Trial: 1622179
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg every 24 h)
Trial: 1622179
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg every 12 h)
Trial: 30600794
Drug: Meaning and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meaning and Purpose (MaP) therapy
Trial: 29129894
Drug: Combination package
RxNorm normalized name: COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination package containing a personalized daughter-directed reminder leaflet and an additional informational leaflet for the mother requesting her recommendation for screening.
Trial: 22330025
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration therapy (9-15 min, frequency = 20-30 Hz, amplitude = 0.44-0.60 mm)
Trial: 28065165
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration therapy
Trial: 19265567
Drug: Compulsory community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compulsory community treatment orders
Trial: 15376806
Drug: Teaching predictive
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching predictive values of features (central or peripheral) for biological properties of animals
Trial: 11400949
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate, 880 microg every 12 hours for 12 weeks from the start date of their CPB conditioning regimen.
Trial: 9744697
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg sublingual glyceryl trinitrate (GTN)
Trial: 18722631
Drug: All Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All Tadalafil doses
Trial: 15778231
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus stabilising exercises
Trial: 12870339
Drug: Hunan aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hunan aqueous drainage (HAD) implantation with mitomycin C (MMC) (0.4 mg/ml, 1 to 5 mins)
Trial: 8757659
Drug: Manually selected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually selected tube potentials with a molybdenum/molybdenum target filter combination
Trial: 7129748
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusions over a two-year period
Trial: 7129748
Drug: Single-blind placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-blind placebo infusion
Trial: 7129748
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusions
Trial: 28942805
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy for Children (DBT-C)
Trial: 15834219
Drug: Low-dose alcoholic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alcoholic beverage (0.4 g/kg)
Trial: 15834219
Drug: High-dose alcoholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alcoholic beverage (0.8 g/kg)
Trial: 1791932
Drug: Alcohol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (both doses)
Trial: 1907056
Drug: Diltiazem (90-360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90-360 mg per day based on body weight)
Trial: 6322505
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg/day for 3 days
Trial: 3709030
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg/day for 6 days
Trial: 6322505
Drug: Miconazole 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole 100 mg/day for 14 days
Trial: 31604631
Drug: Dosing cups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing cups
Trial: 31604631
Drug: Oral syringes
RxNorm normalized name: Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral syringes
Trial: 28274772
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg three times daily for 5 days
Trial: 24284414
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily mesalazine
Trial: 24284414
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily mesalazine
Trial: 22682806
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (Gem) treatment arm with CA 19-9 <90 U/mL
Trial: 22682806
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (Gem) treatment arm with CA 19-9 ≥90 U/mL